Kaderbhaï Courèche, Tharin Zoé, Ghiringhelli François
Department of Medical Oncology. Centre Georges-François Leclerc, 21000 Dijon, France.
Department of medicine, University of Burgundy and Franche-Comté, 21000 Dijon, France.
Cancers (Basel). 2019 Feb 10;11(2):201. doi: 10.3390/cancers11020201.
Immune checkpoint inhibitors radically changed the treatment of patients with non-small cell lung cancer (NSCLC). However, only one-quarter of patients benefit from these new therapies when used as monotherapy. The assessment of Program Death Ligand-1 (PD-L1) tumor expression by immunohistochemistry is used to select potential responder patients, but this not an optimal marker since it does not predict the absence of anti PD-1 efficacy. Despite this shortcoming, PD-L1 remains the gold standard biomarker in many studies and the only biomarker available for clinicians. In addition to histological markers, transcriptomic and exome analyses have revealed potential biomarkers requiring further confirmation. Recently, tumor mutational burden has emerged as a good surrogate marker of outcome. In this review we will detail current knowledge on DNA and RNA related biomarkers.
免疫检查点抑制剂彻底改变了非小细胞肺癌（NSCLC）患者的治疗方式。然而，这些新疗法作为单一疗法使用时，只有四分之一的患者从中受益。通过免疫组织化学评估程序性死亡配体-1（PD-L1）肿瘤表达用于选择潜在的反应性患者，但这并非最佳标志物，因为它无法预测抗PD-1疗效的缺失。尽管存在这一缺点，在许多研究中PD-L1仍然是金标准生物标志物，也是临床医生可用的唯一生物标志物。除了组织学标志物外，转录组和外显子组分析还揭示了需要进一步确认的潜在生物标志物。最近，肿瘤突变负荷已成为一个良好的预后替代标志物。在本综述中，我们将详细阐述目前关于DNA和RNA相关生物标志物的知识。
